EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fixed-Duration First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) in Canada: A Canadian Expert Clinical Framework

Versha Banerji, Isabelle Fleury, Alina Gerrie, Christopher Hillis, Robert Puckrin

Canadian Hematology Today · 12.11.2026 · 2-16

DOI: 10.58931/cht.2026.5s0394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Hematology Today, online erschienen am 12.11.2026. Verfasst von Versha Banerji und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is an indolent B cell malignancy that may present with lymphocytosis, lymphadenopathy, splenomegaly, cytopenias, and/or immune complications.1,2 In 2023, 2,030 people in Canada (excluding Nova Scotia) were diagnosed with CLL, resulting in an incidence rate of 5.2 per 100,000 population.3 The CLL prevalence was projected to increase from 15,512 in 2020 to 19,517 in 2025, driven by rising incidence and longer survival from treatment improvements.4 The treatment landscape for CLL/SLL has evolved substantially with the introduction of multiple targeted therapies that differ in treatment duration, toxicity profile, and logistical complexity. This article discusses the current first-line treatment of CLL/SLL in Canada, focusing on fixed-duration (FD) treatment options that combine venetoclax with obinutuzumab, acalabrutinib, or ibrutinib, and discusses their implications for individualized treatment selection, therapeutic sequencing, and real-world implementation.

Zitieren

APA

Banerji, V., Fleury, I., Gerrie, A., Hillis, C., & Puckrin, R. (2026). Fixed-Duration First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) in Canada: A Canadian Expert Clinical Framework. Canadian Hematology Today, 2-16. https://doi.org/10.58931/cht.2026.5s0394

Vancouver

Banerji V, Fleury I, Gerrie A, Hillis C, Puckrin R. Fixed-Duration First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) in Canada: A Canadian Expert Clinical Framework. Canadian Hematology Today. 2026:2-16. doi:10.58931/cht.2026.5s0394

BibTeX
@article{Banerji2026,
  author = {Banerji, Versha and Fleury, Isabelle and Gerrie, Alina and Hillis, Christopher and Puckrin, Robert},
  title = {Fixed-Duration First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) in Canada: A Canadian Expert Clinical Framework},
  journal = {Canadian Hematology Today},
  year = {2026},
  pages = {2--16},
  doi = {10.58931/cht.2026.5s0394}
}
Kostenlos starten →